That's the key question in hepatology right now. The general principle is that fibrosis up to F3 (bridging fibrosis) is potentially reversible given sufficient stimulus. F4 (cirrhosis) has traditionally been considered irreversible, though there is emerging evidence that early cirrhosis can regress with sustained intervention.

For GLP-1 RAs specifically, the most robust data is in F1-F3 fibrosis. Patients with compensated cirrhosis (F4, Child-Pugh A) were included in some trials, but the numbers are small and the results are mixed. Importantly, GLP-1 RAs should be used with caution in decompensated cirrhosis (ascites, varices, encephalopathy) due to altered drug metabolism and the risk of aspiration with delayed gastric emptying.

For most MASH patients with F2-F3 fibrosis — which is where the greatest clinical urgency lies, as these patients are at highest risk of progression to cirrhosis — the data is very encouraging. Early, aggressive treatment with GLP-1 agonists may prevent the need for liver transplantation in some patients.

I had no idea GLP-1 drugs could help with liver disease. I have elevated ALT (68 U/L) and my PCP told me it's "probably fatty liver" but didn't order imaging or refer me to a specialist. I'm on semaglutide for weight loss. Should I push for a FibroScan to get a baseline?

Absolutely. With an ALT of 68 and presumably metabolic risk factors (since you're on semaglutide for weight management), you should have at minimum a FIB-4 score calculated and ideally a FibroScan or hepatic ultrasound. "Probably fatty liver" deserves more than a shrug.

Steps I'd recommend:

1. Calculate your FIB-4: uses age, AST, ALT, and platelet count. Available on MDCalc.
2. If FIB-4 >1.3 (intermediate risk) or >2.67 (high risk), request a FibroScan or MRI-PDFF to assess steatosis and fibrosis.
3. Get baseline labs: ALT, AST, GGT, albumin, platelet count, INR.
4. Repeat labs every 3-6 months on semaglutide to track response.

The good news: you're already on the right therapy. Semaglutide should improve your liver enzymes and hepatic fat. But getting a baseline allows you to quantify that improvement and catch any advanced fibrosis that might need additional intervention.

Liver health is increasingly recognized as a critical component of cardiometabolic risk management. MASH is projected to become the leading cause of liver transplantation within the next decade. The fact that GLP-1 and GIP agonists address both liver disease and cardiovascular risk simultaneously is one of the most exciting developments in metabolic medicine.

Great thread with actionable clinical information. Pinned for reference.